Screener
Tarsus Pharmaceuticals, Inc. TARS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $40,141 | $16,387 |
| Accrued payroll and benefits | 11,887 | 17,779 |
| Other accrued liabilities | 123,725 | 101,529 |
| Total current liabilities | 175,753 | 135,695 |
| Long-term debt, net | 72,762 | 72,438 |
| Other long-term liabilities | 15,895 | 10,599 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s accrued expenses?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accrued expenses of $11.89M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accrued expenses increased by 2.4% year-over-year, from $11.61M to $11.89M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s accrued expenses has grown at a 76.4% compound annual growth rate (CAGR), from $1.04M to $17.78M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude